Logo

Johnson & Johnson Publishes Interim Results of Single-Shot COVID-19 Vaccine in P-I/IIa Sub-Study for COVID 19 in NEJM

Share this
Johnson & Johnson Publishes Interim Results of Single-Shot COVID-19 Vaccine in P-I/IIa Sub-Study for COVID 19 in NEJM

Johnson & Johnson Publishes Interim Results of Single-Shot COVID-19 Vaccine in P-I/IIa Sub-Study for COVID 19 in NEJM

Shots:

  • The ongoing P-I/IIa sub-study involves evaluating safety- reactogenicity & immunogenicity of COVID-19 vaccine (IM- given as single-dose or two-dose- 8 wks. apart) in adults across multiple clinical sites in Belgium & the US
  • The results demonstrated durable humoral & cellular immune responses in single-shot COVID-19 vaccine @8mos. after immunization & elicits neutralizing Ab activity against Delta variant (B.1.617.2) & other SARS-CoV-2 variants of concern
  • The results from a new analysis of blood samples in the P-III ENSEMBLE study showed that the single-shot COVID-19 vaccine- induced neutralizing Ab activity against the Delta variant at a higher level

  Ref: J&J | Image: Actualidad RT

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions